Lymphocyte Activation Gene – 3 Protein Market Demand 2019 to Escalated by Automation of Processes Overview on 10 Companies Based on the Product, Component and End-User

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Immune checkpoint receptors such as lymphocyte activation gene-3 (LAG-3) protein are found on cell surface of effector T cells and regulatory T cells (Tregs). T cells are type of white blood cells that eliminate unhealthy or foreign cells, which enter the immune system. Function of lymphocyte activation gene-3 protein is to control T cell response, activation, and growth. Lymphocyte activation gene-3 turns off the immune response, when a T cell is activated to eliminate a target cell. This prevents the T cells from harming healthy cells. Moreover, lymphocyte activation gene-3 protein is associated with T cell exhaustion, in which the T cells become desensitized and lose their ability to function.

Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2027

LAG-3 is closely associated with regulation of cytotoxic T cells and regulatory T cells, which has attracted attention of researchers and manufacturers as a therapeutic target against cancer. In cancers, lymphocyte activation gene-3 expressing exhausted cytotoxic T cells and regulatory T cells (Tregs) are found to be gathered at tumor locations. Recent studies reported that inhibiting LAG-3 functions allows T cells to regain their cytotoxic function and affect tumor growth. There are several LAG-3 protein antibodies in the clinical trials, which are expected to further advance in clinical trials over the forecast period.

Lymphocyte Activation Gene-3 Protein Market Drivers

Several drugs in clinical trials that target the LAG-3 protein, is expected to be a major factor contributing in global lymphocyte activation gene-3 protein market growth over the forecast period. These drugs are still in the clinical trials in different phases. For instance, in 2017, BMS-986016 (Relatlimab) developed by Bristol-Myers Squibb in combination with Opdivo (nivolumab), effectively aided in treatment of advanced melanoma that was previously treated with anti-PD-1/PD-L1 therapy. The drug is in phase II clinical trial and its estimated study completion date is March 16, 2022.

Moreover, several other drugs such as MGD013 sponsored by MacroGenics (estimated study completion date – August 2022) and IMP321 (eftilagimod alpha) by Immutep (estimated study completion date is August 2019) are in Phase 1 clinical trials, and this is expected drive global LAG-3 protein market growth over the forecast period.

Manufacturers and researchers are focused on development of novel therapies that aid in treatment of cancer. High prevalence of cancer is expected to boost growth of the market. According to National Cancer Institute, around 1,735,350 new cases of cancer are expected to be diagnosed in the U.S., in 2018. The most common types of cancer include lung cancer, breast cancer, prostate cancer, melanoma, bladder cancer, and others. According to Cancer Research UK, 2015, around 54,900 new cases of breast cancer were registered in the U.K., which accounted for 15% of all new cancer cases, annually.

However, uncertainty of clinical trials (as drugs may fail to show efficacy even in late phases of clinical trials) is expected to restrain the lymphocyte activation gene – 3 protein market growth over the forecast period.

Lymphocyte Activation Gene – 3 Protein Market Regional Insights

North America is expected to witness significant growth in the LAG -3 protein market over the forecast period. Robust pipeline of LAG-3 protein antibodies and increasing demand for such drugs is expected to facilitate growth of the market, in the U.S. For instance, Bristol-Myers Squibb has Relatlimab in phase II clinical trials and Regeneron Pharmaceuticals Inc., in collaboration with Sanofi, has REGN3767 in phase I clinical trials, 2017.

Browse Research Report : https://www.coherentmarketinsights.com/ongoing-insight/lymphocyte-activation-gene-3-protein-market-2027

High prevalence of various types of cancer in North America, Europe, and Asia Pacific is expected to be a major factor contributing growth of the lymphocyte activation gene – 3 protein market over the forecast period. For instance, according to the European Union (EU), in 2014, almost 1/3^rd million people died from cancer in the EU-28. Moreover, manufacturers are focused on conducting clinical trials in these regions to expand their potential customer base.

Lymphocyte Activation Gene-3 Protein Market Key Player

Key players operating in the global lymphocyte activation gene-3 protein market include Bristol-Myers Squibb, Icell Kealex Therapeutics, Incyte Corporation, MacroGenics, Inc., GlaxoSmithKline Plc, Crescendo Biologics Ltd, Regeneron Pharmaceuticals Inc., Sutro Biopharma Inc., Symphogen A/S, and Immutep Ltd.

Lymphocyte Activation Gene 3 Protein Market Taxonomy

The global lymphocyte activation gene-3 protein market is segmented on the basis of drug, cancer type, and region.

By Drug –

• BMS-986016 (Relatlimab)
• IMP321
• IMP701
• MGD013
• Others

By Cancer Type –

• Breast Cancer
• Melanoma
• Solid Tumors
• Others

By Region –

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.